Treatment options for alcoholic and non-alcoholic fatty liver disease: A review

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are serious health problems worldwide. These two diseases have similar pathological spectra, ranging from simple steatosis to hepatitis to cirrhosis and hepatocellular carcinoma. Although most people with excessive alcohol or calorie intake display abnormal fat accumulation in the liver (simple steatosis), a small percentage develops progressive liver disease. Despite extensive research on understanding the pathophysiology of both these diseases there are still no targeted therapies available. The treatment for ALD remains as it was 50 years ago: abstinence, nutritional support and corticosteroids (or pentoxifylline as an alternative if steroids are contraindicated). As for NAFLD, the treatment modality is mainly directed toward weight loss and co-morbidity management. Therefore, new pathophysiology directed therapies are urgently needed. However, the involvement of several inter-related pathways in the pathogenesis of these diseases suggests that a single therapeutic agent is unlikely to be an effective treatment strategy. Hence, a combination therapy towards multiple targets would eventually be required. In this review, we delineate the treatment options in ALD and NAFLD, including various new targeted therapies that are currently under investigation. We hope that soon we will be having an effective multi-therapeutic regimen for each disease.

Original languageEnglish (US)
Pages (from-to)6549-6570
Number of pages22
JournalWorld Journal of Gastroenterology
Volume23
Issue number36
DOIs
StatePublished - Sep 28 2017

Fingerprint

Alcoholic Liver Diseases
Therapeutics
Non-alcoholic Fatty Liver Disease
Pentoxifylline
Nutritional Support
Fatty Liver
Hepatitis
Liver Diseases
Weight Loss
Hepatocellular Carcinoma
Adrenal Cortex Hormones
Fibrosis
Fats
Steroids
Alcohols
Morbidity
Research

Keywords

  • Alcoholic liver disease
  • Glucocorticoids
  • Liver transplantation
  • Non-alcoholic fatty liver disease
  • Treatment options

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Treatment options for alcoholic and non-alcoholic fatty liver disease : A review. / Singh, Sukhpreet; Osna, Natalia A; Kharbanda, Kusum.

In: World Journal of Gastroenterology, Vol. 23, No. 36, 28.09.2017, p. 6549-6570.

Research output: Contribution to journalReview article

@article{78c8a7b073db4277b6fd000ac0601920,
title = "Treatment options for alcoholic and non-alcoholic fatty liver disease: A review",
abstract = "Alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are serious health problems worldwide. These two diseases have similar pathological spectra, ranging from simple steatosis to hepatitis to cirrhosis and hepatocellular carcinoma. Although most people with excessive alcohol or calorie intake display abnormal fat accumulation in the liver (simple steatosis), a small percentage develops progressive liver disease. Despite extensive research on understanding the pathophysiology of both these diseases there are still no targeted therapies available. The treatment for ALD remains as it was 50 years ago: abstinence, nutritional support and corticosteroids (or pentoxifylline as an alternative if steroids are contraindicated). As for NAFLD, the treatment modality is mainly directed toward weight loss and co-morbidity management. Therefore, new pathophysiology directed therapies are urgently needed. However, the involvement of several inter-related pathways in the pathogenesis of these diseases suggests that a single therapeutic agent is unlikely to be an effective treatment strategy. Hence, a combination therapy towards multiple targets would eventually be required. In this review, we delineate the treatment options in ALD and NAFLD, including various new targeted therapies that are currently under investigation. We hope that soon we will be having an effective multi-therapeutic regimen for each disease.",
keywords = "Alcoholic liver disease, Glucocorticoids, Liver transplantation, Non-alcoholic fatty liver disease, Treatment options",
author = "Sukhpreet Singh and Osna, {Natalia A} and Kusum Kharbanda",
year = "2017",
month = "9",
day = "28",
doi = "10.3748/wjg.v23.i36.6549",
language = "English (US)",
volume = "23",
pages = "6549--6570",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "36",

}

TY - JOUR

T1 - Treatment options for alcoholic and non-alcoholic fatty liver disease

T2 - A review

AU - Singh, Sukhpreet

AU - Osna, Natalia A

AU - Kharbanda, Kusum

PY - 2017/9/28

Y1 - 2017/9/28

N2 - Alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are serious health problems worldwide. These two diseases have similar pathological spectra, ranging from simple steatosis to hepatitis to cirrhosis and hepatocellular carcinoma. Although most people with excessive alcohol or calorie intake display abnormal fat accumulation in the liver (simple steatosis), a small percentage develops progressive liver disease. Despite extensive research on understanding the pathophysiology of both these diseases there are still no targeted therapies available. The treatment for ALD remains as it was 50 years ago: abstinence, nutritional support and corticosteroids (or pentoxifylline as an alternative if steroids are contraindicated). As for NAFLD, the treatment modality is mainly directed toward weight loss and co-morbidity management. Therefore, new pathophysiology directed therapies are urgently needed. However, the involvement of several inter-related pathways in the pathogenesis of these diseases suggests that a single therapeutic agent is unlikely to be an effective treatment strategy. Hence, a combination therapy towards multiple targets would eventually be required. In this review, we delineate the treatment options in ALD and NAFLD, including various new targeted therapies that are currently under investigation. We hope that soon we will be having an effective multi-therapeutic regimen for each disease.

AB - Alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are serious health problems worldwide. These two diseases have similar pathological spectra, ranging from simple steatosis to hepatitis to cirrhosis and hepatocellular carcinoma. Although most people with excessive alcohol or calorie intake display abnormal fat accumulation in the liver (simple steatosis), a small percentage develops progressive liver disease. Despite extensive research on understanding the pathophysiology of both these diseases there are still no targeted therapies available. The treatment for ALD remains as it was 50 years ago: abstinence, nutritional support and corticosteroids (or pentoxifylline as an alternative if steroids are contraindicated). As for NAFLD, the treatment modality is mainly directed toward weight loss and co-morbidity management. Therefore, new pathophysiology directed therapies are urgently needed. However, the involvement of several inter-related pathways in the pathogenesis of these diseases suggests that a single therapeutic agent is unlikely to be an effective treatment strategy. Hence, a combination therapy towards multiple targets would eventually be required. In this review, we delineate the treatment options in ALD and NAFLD, including various new targeted therapies that are currently under investigation. We hope that soon we will be having an effective multi-therapeutic regimen for each disease.

KW - Alcoholic liver disease

KW - Glucocorticoids

KW - Liver transplantation

KW - Non-alcoholic fatty liver disease

KW - Treatment options

UR - http://www.scopus.com/inward/record.url?scp=85030148751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030148751&partnerID=8YFLogxK

U2 - 10.3748/wjg.v23.i36.6549

DO - 10.3748/wjg.v23.i36.6549

M3 - Review article

C2 - 29085205

AN - SCOPUS:85030148751

VL - 23

SP - 6549

EP - 6570

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 36

ER -